Search

Your search keyword '"Asimakopoulos, Fotis"' showing total 232 results
Start Over Author "Asimakopoulos, Fotis"
232 results on '"Asimakopoulos, Fotis"'

1. Protocol to identify and isolate rare murine tumor-resident dendritic cell populations for low-input transcriptomic profiling.

Author

Papadas, Athanasios, Lagal, Daniel, Dou, Yaling, Hong, Duncan, Gibbons, Alicia, Cicala, Alexander, Huang, Yun, Zomalan, Brolyn, Molina, Elsa, and Asimakopoulos, Fotis

Subjects
Cancer, Cell Biology, Cell culture, Cell isolation, Flow Cytometry, Immunology, Model Organisms, Molecular Biology, RNA-seq, Sequencing
Abstract

Conventional type 1 dendritic cells (cDC1s) are critical for innate sensing of cancer, yet they are scarce in the tumor microenvironment (TME). Here, we present a protocol to identify and isolate cDC1 subsets from murine implantable tumors for subsequent transcriptomic profiling using a flow sorting-based strategy. We describe steps for cell culture of mouse tumors, tumoral growth, dissociation and isolation of tumoral cells, extracellular staining, and cell sorting. We then detail procedures for RNA isolation, mRNA library preparation, and sequencing. For complete details on the use and execution of this protocol, please refer to Papadas et al.1.

Published
2024

2. Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity.

Author

Papadas, Athanasios, Huang, Yun, Cicala, Alexander, Dou, Yaling, Fields, Matteo, Gibbons, Alicia, Hong, Duncan, Lagal, Daniel J, Quintana, Victoria, Rizo, Alejandro, Zomalan, Brolyn, and Asimakopoulos, Fotis

Subjects
Biochemistry and Cell Biology, Biological Sciences, Immunization, Cancer, Inflammatory and immune system, T-cells, antigen presentation, cancer, dendritic cells, stroma, vaccines, Medical Biochemistry and Metabolomics, Biochemistry & Molecular Biology, Biochemistry and cell biology
Abstract

Advances in immunotherapy in the last decade have revolutionized treatment paradigms across multiple cancer diagnoses. However, only a minority of patients derive durable benefit and progress with traditional approaches, such as cancer vaccines, remains unsatisfactory. A key to overcoming these barriers resides with a deeper understanding of tumor antigen presentation and the complex and dynamic heterogeneity of tumor-infiltrating antigen-presenting cells (APCs). Reminiscent of the 'second touch' hypothesis proposed by Klaus Ley for CD4+ T cell differentiation, the acquisition of full effector potential by lymph node- primed CD8+ T cells requires a second round of co-stimulation at the site where the antigen originated, i.e. the tumor bed. The tumor stroma holds a prime role in this process by hosting specialized APC niches, apparently distinct from tertiary lymphoid structures, that support second antigenic touch encounters and CD8+ T cell effector proliferation and differentiation. We propose that APC within second-touch niches become licensed for co-stimulation through stromal-derived instructive signals emulating embryonic or wound-healing provisional matrix remodeling. These immunostimulatory roles of stroma contrast with its widely accepted view as a physical and functional 'immune barrier'. Stromal control of antigen presentation makes evolutionary sense as the host stroma-tumor interface constitutes the prime line of homeostatic 'defense' against the emerging tumor. In this review, we outline how stroma-derived signals and cells regulate tumor antigen presentation and T-cell effector differentiation in the tumor bed. The re-definition of tumor stroma as immune rheostat rather than as inflexible immune barrier harbors significant untapped therapeutic opportunity.

Published
2023

3. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Author

Holstein, Sarah, Asimakopoulos, Fotis, Azab, Abdel, Bianchi, Giada, Bhutani, Manisha, Crews, Leslie, Cupedo, Tom, Giles, Hannah, Gooding, Sarah, Hillengass, Jens, John, Lukas, Kaiser, Shari, Lee, Lydia, Maclachlan, Kylee, Pasquini, Marcelo, Pichiorri, Flavia, Shokeen, Monica, Shy, Brian, Smith, Eric, Verona, Raluca, Usmani, Saad, McCarthy, Philip, and Shah, Nina

Subjects
CAR T cell, Imaging, Multiple myeloma, Resistance, Tumor microenvironment, Bone Marrow, Cell- and Tissue-Based Therapy, Clinical Trials as Topic, Humans, Multiple Myeloma
Abstract

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on January 7, 2022. This workshop included presentations by basic, translational, and clinical researchers with expertise in plasma cell dyscrasias. Four main topics were discussed: platforms for myeloma disease evaluation, insights into pathophysiology, therapeutic target and resistance mechanisms, and cellular therapy for multiple myeloma. Here we provide a comprehensive summary of these workshop presentations.

Published
2022

5. Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer

Author

Deichaite, Ida, Sears, Timothy J, Sutton, Leisa, Rebibo, Daniel, Morgan, Kylie, Nelson, Tyler, Rose, Brent, Tamayo, Pablo, Ferrara, Napoleone, Asimakopoulos, Fotis, and Carter, Hannah

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Prostate Cancer, Urologic Diseases, Aging, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Male, Humans, Immune Evasion, Interleukin-6, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor Inhibitors, Prostatic Neoplasms, Inflammation, Tumor Microenvironment, Prostate cancer, TNF, IL-6, ADAMTS-4, AP-1, FOSB, Bevacizumab, SELE, Macrophage polarization, Immune remodeling, prostate cancer, bevacizumab, macrophage polarization, immune remodeling, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundThe role of the inflammatory milieu in prostate cancer progression is not well understood. Differences in inflammatory signaling between localized and metastatic disease may point to opportunities for early intervention.MethodsWe modeled PCa disease progression by analyzing RNA-seq of localized vs. metastatic patient samples, followed by CIBERSORTx to assess their immune cell populations. The VHA CDW registry of PCa patients was analyzed for anti-TNF clinical outcomes.ResultsWe observed statistically significant opposing patterns of IL-6 and TNFα expression between localized and metastatic disease. IL-6 was robustly expressed in localized disease and downregulated in metastatic disease. The reverse was observed with TNFα expression. Metastatic disease was also characterized by downregulation of adhesion molecule E-selectin, matrix metalloproteinase ADAMTS-4 and a shift to M2 macrophages whereas localized disease demonstrated a preponderance of M1 macrophages. Treatment with anti-TNF agents was associated with earlier stage disease at diagnosis.ConclusionsOur data points to clearly different inflammatory contexts between localized and metastatic prostate cancer. Primary localized disease demonstrates local inflammation and adaptive immunity, whereas metastases are characterized by immune cold microenvironments and a shift towards resolution of inflammation and tissue repair. Therapies that interfere with these inflammatory networks may offer opportunities for early intervention in monotherapy or in combination with immunotherapies and anti-angiogenic approaches.

Published
2022

6. Versican in Tumor Progression, Tumor–Host Interactions, and Cancer Immunotherapy

Author

Papadas, Athanasios, Cicala, Alexander, Kraus, Sean G., Arauz, Garrett, Tong, Alexander, Deming, Dustin, Asimakopoulos, Fotis, Karamanos, Nikos K., Series Editor, Kletsas, Dimitris, Editorial Board Member, Oh, Eok-Soo, Editorial Board Member, Passi, Alberto, Editorial Board Member, Pihlajaniemi, Taina, Editorial Board Member, Ricard-Blum, Sylvie, Editorial Board Member, Sagi, Irit, Editorial Board Member, Savani, Rashmin, Editorial Board Member, Watanabe, Hideto, Editorial Board Member, Kovalszky, Ilona, editor, Franchi, Marco, editor, and Alaniz, Laura D., editor

Published
2022
Full Text
View/download PDF

8. Versican in the Tumor Microenvironment

Author

Papadas, Athanasios, Asimakopoulos, Fotis, Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, and Birbrair, Alexander, editor

Published
2020
Full Text
View/download PDF

10. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice

Author

Wen, Zhi, Rajagopalan, Adhithi, Flietner, Evan D., Yun, Grant, Chesi, Marta, Furumo, Quinlan, Burns, Robert T., Papadas, Athanasios, Ranheim, Erik A., Pagenkopf, Adam C., Morrow, Zachary T., Finn, Remington, Zhou, Yun, Li, Shuyi, You, Xiaona, Jensen, Jeffrey, Yu, Mei, Cicala, Alexander, Menting, James, Mitsiades, Constantine S., Callander, Natalie S., Bergsagel, P. Leif, Wang, Demin, Asimakopoulos, Fotis, and Zhang, Jing

Published
2021
Full Text
View/download PDF

12. Mechanisms of Resistance in Multiple Myeloma

Author

Papadas, Athanasios, Asimakopoulos, Fotis, Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Series Editor, Frohman, Michael A., Series Editor, Geppetti, Pierangelo, Series Editor, Hofmann, Franz B., Series Editor, Michel, Martin C., Series Editor, Page, Clive P., Series Editor, Rosenthal, Walter, Series Editor, Wang, KeWei, Series Editor, Mandalà, Mario, editor, and Romano, Emanuela, editor

Published
2018
Full Text
View/download PDF

13. P-376 Genomic and transcriptional profiling stratifies myeloma models into two clusters with distinct risk signatures and drug responses

Author

Flietner, Evan, primary, Yu, Mei, additional, Poudel, Govinda, additional, Veltri, Anthony, additional, Zhou, Yun, additional, Rajagopalan, Adhithi, additional, Feng, Yubin, additional, Lasho, Terra, additional, Wen, Zhi, additional, Sun, Yuqian, additional, Patnaik, Mrinal, additional, Callander, Natalie S., additional, Asimakopoulos, Fotis, additional, Wang, Demin, additional, and Zhang, Jing, additional

Published
2023
Full Text
View/download PDF

14. Supplemental Tables 1 - 2, Figures 1 - 3 from Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma

Author

Jensen, Jeffrey Lee, primary, Rakhmilevich, Alexander, primary, Heninger, Erika, primary, Broman, Aimee Teo, primary, Hope, Chelsea, primary, Phan, Funita, primary, Miyamoto, Shigeki, primary, Maroulakou, Ioanna, primary, Callander, Natalie, primary, Hematti, Peiman, primary, Chesi, Marta, primary, Bergsagel, P. Leif, primary, Sondel, Paul, primary, and Asimakopoulos, Fotis, primary

Published
2023
Full Text
View/download PDF

15. Data from Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma

Author

Jensen, Jeffrey Lee, primary, Rakhmilevich, Alexander, primary, Heninger, Erika, primary, Broman, Aimee Teo, primary, Hope, Chelsea, primary, Phan, Funita, primary, Miyamoto, Shigeki, primary, Maroulakou, Ioanna, primary, Callander, Natalie, primary, Hematti, Peiman, primary, Chesi, Marta, primary, Bergsagel, P. Leif, primary, Sondel, Paul, primary, and Asimakopoulos, Fotis, primary

Published
2023
Full Text
View/download PDF

16. Heart-liver-kidney transplantation for AL amyloidosis using normothermic recovery and storage from a donor following circulatory death: Short-term outcome in a first-in-world experience

Author

Brubaker, Aleah L., primary, Urey, Marcus A., additional, Taj, Raeda, additional, Parekh, Justin R., additional, Berumen, Jennifer, additional, Kearns, Mark, additional, Shah, Mita, additional, Khan, Adnan, additional, Kono, Yuko, additional, Ajmera, Veeral, additional, Barman, Pranab, additional, Tran, Hao, additional, Adler, Eric D., additional, Silva Enciso, Jorge, additional, Asimakopoulos, Fotis, additional, Costello, Caitlin, additional, Bower, Richard, additional, Sanchez, Ramon, additional, Pretorius, Victor, additional, and Schnickel, Gabriel T., additional

Published
2023
Full Text
View/download PDF

17. Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses

Author

Flietner, Evan, primary, Yu, Mei, additional, Rajagopalan, Adhithi, additional, Zhou, Yun, additional, Feng, Yubin, additional, Veltri, Anthony, additional, Lasho, Terra, additional, Wen, Zhi, additional, Sun, Yuqian, additional, Burns, Robert, additional, Patnaik, Mrinal M., additional, Callander, Natalie, additional, Asimakopoulos, Fotis, additional, Wang, Demin, additional, and Zhang, Jing, additional

Published
2022
Full Text
View/download PDF

22. Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment

Author

Papadas, Athanasios, primary, Deb, Gauri, additional, Cicala, Alexander, additional, Officer, Adam, additional, Hope, Chelsea, additional, Pagenkopf, Adam, additional, Flietner, Evan, additional, Morrow, Zachary T., additional, Emmerich, Philip, additional, Wiesner, Joshua, additional, Arauz, Garrett, additional, Bansal, Varun, additional, Esbona, Karla, additional, Capitini, Christian M., additional, Matkowskyj, Kristina A., additional, Deming, Dustin A., additional, Politi, Katerina, additional, Abrams, Scott I., additional, Harismendy, Olivier, additional, and Asimakopoulos, Fotis, additional

Published
2022
Full Text
View/download PDF

26. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis

Author

Ma, Shi-Dong, Xu, Xuequn, Plowshay, Julie, Ranheim, Erik A., Burlingham, William J., Jensen, Jeffrey L., Asimakopoulos, Fotis, Tang, Weihua, Gulley, Margaret L., Cesarman, Ethel, Gumperz, Jenny E., and Kenney, Shannon C.

Subjects
T cells -- Analysis -- Health aspects -- Physiological aspects -- Research, Non-Hodgkin's lymphomas -- Analysis -- Health aspects -- Risk factors -- Research, Epstein-Barr virus -- Analysis -- Health aspects -- Research, Health care industry
Abstract

Epstein-Barr virus (EBV) infection transforms B cells in vitro and is associated with human B cell lymphomas. The major EBV oncoprotein, latent membrane protein 1 (LMP1), mimics constitutively active CD40 and is essential for outgrowth of EBV-transformed B cells in vitro; however, EBV-positive diffuse large B cell lymphomas and Burkitt lymphomas often express little or no LMP1. Thus, EBV may contribute to the development and maintenance of human lymphomas even in the absence of LMP1. Here, we found that i.p. injection of human cord blood mononuclear cells infected with a LMP1-deficient EBV into immunodeficient mice induces B cell lymphomas. In this model, lymphoma development required the presence of [CD4.sup.+] T cells in cord blood and was inhibited by CD40-blocking Abs. In contrast, LMP1-deficient EBV established persistent latency but did not induce lymphomas when directly injected into mice engrafted with human fetal [CD34.sup.+] cells and human thymus. WT EBV induced lymphomas in both mouse models and did not require coinjected T cells in the cord blood model. Together, these results demonstrate that LMP1 is not essential for EBV-induced lymphomas in vivo and suggest that T cells supply signals that substitute for LMP1 in EBV-positive B cell lymphomagenesis., Introduction The human herpesvirus Epstein-Barr virus (EBV) is associated with various B cell lymphomas, including Burkitt lymphoma (BL), Hodgkin lymphoma (HL), lymphoproliferative disease (LPD) in immunocompromised hosts, and diffuse large [...]

Published
2015
Full Text
View/download PDF

27. Ponatinib for RAS-Driven Multiple Myeloma: Efficacy in the High-Risk VQ Myeloma Model

Author

Flietner, Evan, primary, Wen, Zhi, additional, Rajagopalan, Adhithi, additional, Jung, Oisun, additional, Wiesner, Joshua, additional, You, Xiaona, additional, Zhou, Yun, additional, Kingstad-Bakke, Brock, additional, Callander, Natalie, additional, Rapraeger, Alan, additional, Suresh, M., additional, Asimakopoulos, Fotis, additional, and Zhang, Jing, additional

Published
2022
Full Text
View/download PDF

29. Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment

Author

Papadas, Athanasios, primary, Deb, Gauri, additional, Officer, Adam, additional, Cicala, Alexander, additional, Hope, Chelsea, additional, Emmerich, Philip, additional, Wiesner, Joshua, additional, Pagenkopf, Adam, additional, Arauz, Garrett, additional, Bansal, Varun, additional, Matkowskyj, Kristina A., additional, Deming, Dustin, additional, Politi, Katerina, additional, Abrams, Scott I., additional, Harismendy, Olivier, additional, and Asimakopoulos, Fotis, additional

Published
2021
Full Text
View/download PDF

30. 936 Stromal remodeling regulates dendritic cell abundance in the tumor microenvironment

Author

Papadas, Athanasios, primary, Deb, Gauri, additional, Officer, Adam, additional, Hope, Chelsea, additional, Emmerich, Philip, additional, Cicala, Alexander, additional, Wiesner, Joshua, additional, Arauz, Garrett, additional, Pagenkopf, Adam, additional, Matkowskyj, Kristina, additional, Deming, Dustin, additional, Politi, Katerina, additional, Abrams, Scott, additional, Harismendy, Olivier, additional, and Asimakopoulos, Fotis, additional

Published
2021
Full Text
View/download PDF

31. Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network

Author

Callander, Natalie, Markovina, Stephanie, Eickhoff, Jens, Hutson, Paul, Campbell, Toby, Hematti, Peiman, Go, Ronald, Hegeman, Robert, Longo, Walter, Williams, Eliot, Asimakopoulos, Fotis, and Miyamoto, Shigeki

Published
2014
Full Text
View/download PDF

32. Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma.

Author

D'Angelo, Christopher, Sudakaran, Sailendharan, Asimakopoulos, Fotis, Hematti, Peiman, El-Gamal, Dalia, Safdar, Nasia, and Callander, Natalie

Subjects
STEM cell transplantation, MULTIPLE myeloma, GUT microbiome, CELLULAR therapy, HEMATOLOGIC malignancies
Abstract

The gut microbiome is an important feature of host immunity with associations to hematologic malignancies and cellular therapy. We evaluated the gut microbiome and dietary intake in patients with multiple myeloma undergoing autologous stem cell transplantation. Thirty patients were enrolled, and samples were collected at four timepoints: pre-transplant, engraftment, day +100 (D + 100), and 9–12 months post-transplant. Microbiome analysis demonstrated a loss of alpha diversity at the engraftment timepoint driven by decreases in Blautia, Ruminococcus, and Faecalibacterium genera and related to intravenous antibiotic exposure. Higher fiber intake was associated with increased relative abundance of Blautia at the pre-transplant timepoint. Lower alpha diversity at engraftment was associated with a partial response to therapy compared with complete response (CR) or very good partial response (VGPR) (CR/VGPR vs. PR, p < 0.05). We conclude that loss of bacterial diversity at engraftment may be associated with impaired response to stem cell transplantation in multiple myeloma. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice

Author

Wen, Zhi, primary, Rajagopalan, Adhithi, additional, Flietner, Evan D., additional, Yun, Grant, additional, Chesi, Marta, additional, Furumo, Quinlan, additional, Burns, Robert T., additional, Papadas, Athanasios, additional, Ranheim, Erik A., additional, Pagenkopf, Adam C., additional, Morrow, Zachary T., additional, Finn, Remington, additional, Zhou, Yun, additional, Li, Shuyi, additional, You, Xiaona, additional, Jensen, Jeffrey, additional, Yu, Mei, additional, Cicala, Alexander, additional, Menting, James, additional, Mitsiades, Constantine S., additional, Callander, Natalie S., additional, Bergsagel, P. Leif, additional, Wang, Demin, additional, Asimakopoulos, Fotis, additional, and Zhang, Jing, additional

Published
2021
Full Text
View/download PDF

36. Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model

Author

Flietner, Evan, primary, Wen, Zhi, additional, Rajagopalan, Adhithi, additional, Wiesner, Joshua, additional, You, Xiaona, additional, Zhou, Yun, additional, Lasho, Terra, additional, Patnaik, Mrinal M., additional, Wang, Demin, additional, Burns, Robert, additional, Callander, Natalie S., additional, Asimakopoulos, Fotis, additional, and Zhang, Jing, additional

Published
2020
Full Text
View/download PDF

39. Abstract 5733: Versican proteolytic fragments (matrikines) synergize with STING agonists to elicit robust anti-tumor CD8+ T cell responses

Author

Papadas, Athanasios, primary, Flietner, Evan, additional, Morrow, Zachary, additional, Wiesner, Joshua, additional, Cicala, Alexander, additional, Pagenkopf, Adam, additional, Hope, Chelsea, additional, Emmerich, Philip, additional, Deming, Dustin, additional, Zhang, Jing, additional, Hematti, Peiman, additional, Callander, Natalie, additional, Rakhmilevich, Alexander, additional, Otto, Mario, additional, Capitini, Christian, additional, and Asimakopoulos, Fotis, additional

Published
2020
Full Text
View/download PDF

41. VCAN accumulation and proteolysis as predictors of T lymphocyte-excluded and permissive tumor microenvironments.

Author

Emmerich, Philip, primary, Matkowskyj, Kristina A., additional, McGregor, Stephanie, additional, Kraus, Sean, additional, Bischel, Kristen, additional, Qyli, Tonela, additional, Buehler, Darya, additional, Pasch, Cheri, additional, Babiarz, Christopher, additional, Depke, Mitchell, additional, Clipson, Linda, additional, Wisinski, Kari Braun, additional, Burkard, Mark E., additional, Baschnagel, Andrew, additional, Uboha, Nataliya Volodymyrivna, additional, Asimakopoulos, Fotis, additional, and Deming, Dustin A., additional

Published
2020
Full Text
View/download PDF

43. Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination

Author

Papadas, Athanasios, primary, Flietner, Evan, additional, Morrow, Zachary, additional, Wiesner, Joshua, additional, Cicala, Alexander, additional, Pagenkopf, Adam, additional, Hope, Chelsea L., additional, Rajagopalan, Adhithi, additional, Wen, Zhi, additional, Emmerich, Philip, additional, Deming, Dustin, additional, Miyamoto, Shigeki, additional, Hematti, Peiman, additional, Callander, Natalie Scott, additional, Rakhmilevich, Alexander, additional, Otto, Mario, additional, Capitini, Christian M., additional, Zhang, Jing, additional, and Asimakopoulos, Fotis, additional

Published
2019
Full Text
View/download PDF

44. Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Author

Dhakal, Binod, primary, Mushtaq, Muhammad Umair, additional, Cunningham, Ashley, additional, Papadas, Athanasios, additional, Pagenkopf, Adam, additional, Wiesner, Joshua, additional, Leith, Catherine, additional, Hematti, Peiman, additional, Hari, Parameswaran, additional, Callander, Natalie Scott, additional, and Asimakopoulos, Fotis, additional

Published
2019
Full Text
View/download PDF

46. Abstract 1904: Versican production is driven by both epithelial and stromal cells in pancreatic cancer

Author

Rainiero, Hanna R., primary, Emmerich, Philip B., additional, Sievers, Chelsie K., additional, Maloney, Connor J., additional, Pitera, Rosabella T., additional, Payne, Susan N., additional, Depke, Mitchell G., additional, Pasch, Cheri A., additional, Clipson, Linda, additional, Johnson, Jillian K., additional, Matkowskyj, Kristina A., additional, Asimakopoulos, Fotis, additional, and Deming, Dustin A., additional

Published
2019
Full Text
View/download PDF

47. Abstract 3209: BLZ945 and anti-PD-1 combination immunotherapy modulates the immune landscape in pancreatic ductal adenocarcinoma

Author

Sievers, Chelsie K., primary, Emmerich, Philip B., additional, Rainiero, Hanna R., additional, Maloney, Connor, additional, Pitera, Rosabella, additional, Pasch, Cheri A., additional, Clipson, Linda, additional, Matkowskyj, Kristina A., additional, Asimakopoulos, Fotis, additional, and Deming, Dustin A., additional

Published
2019
Full Text
View/download PDF

48. Abstract 1909: Stromal cell driven proteolysis of versican is limited by epithelial cells in pancreatic ductal adenocarcinoma

Author

Emmerich, Philip B., primary, Sievers, Chelsie, additional, Rainiero, Hanna, additional, Pitera, Rosabella, additional, Maloney, Connor, additional, Payne, Susan, additional, Depke, Mitchell, additional, Pasch, Cheri, additional, Clipson, Linda, additional, Johnson, Jillian K., additional, Matkowskyj, Kristina, additional, Asimakopoulos, Fotis, additional, and Deming, Dustin A., additional

Published
2019
Full Text
View/download PDF

50. Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma

Author

Dhakal, Binod, primary, Pagenkopf, Adam, additional, Mushtaq, Muhammad Umair, additional, Cunningham, Ashley M., additional, Flietner, Evan, additional, Morrow, Zachary, additional, Papadas, Athanasios, additional, Hope, Chelsea, additional, Leith, Catherine, additional, Hematti, Peiman, additional, Hari, Parameswaran, additional, Callander, Natalie S., additional, and Asimakopoulos, Fotis, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results